Siahbazi Shiva, Behboudi-Gandevani Samira, Moghaddam-Banaem Lida, Montazeri Ali
School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran.
Department of Midwifery and Reproductive Health, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
J Obstet Gynaecol Res. 2017 May;43(5):887-894. doi: 10.1111/jog.13299. Epub 2017 Feb 11.
The purpose of study was to assess the effect of zinc sulfate (ZS) supplementation on premenstrual syndrome (PMS) and health-related quality of life (QoL).
This was a double-blind randomized and placebo-controlled trial using the parallel technique conducted between June 2013 and May 2014. A total of 142 women (age, 20-35 years) with PMS were allocated to either the ZS or placebo group. The women in the intervention group received ZS 220-mg capsules (containing 50 mg elemental zinc) from the 16th day of the menstrual cycle to the second day of the next cycle. Data were collected using the Premenstrual Symptoms Screening Tool (PSST) and 12-item Short-Form Health Survey Questionnaire.
The prevalence of moderate to severe PMS in the ZS group significantly decreased throughout the study period (9.5% in the first, 6% in the second and 2.6% in the third month of the study, P < 0.001), but in the control placebo group this reduction was seen only in the first month of the study (14.2% in the first, 13.7% in the second and 13.5% in the third month, P = 0.08). Also, ZS improved the PSST component scores throughout the study period. The mean scores of QoL in physical and mental components were significantly improved in the ZS intervention group. However, the differences were statistically significant only 3 months after the intervention.
Zinc sulfate, as a simple and inexpensive treatment, was associated with improvement of PMS symptoms and health-related QoL. Additional studies are warranted to confirm these findings.
本研究旨在评估补充硫酸锌（ZS）对经前综合征（PMS）及健康相关生活质量（QoL）的影响。
这是一项采用平行技术的双盲随机安慰剂对照试验，于2013年6月至2014年5月进行。共有142名患有经前综合征的女性（年龄20 - 35岁）被分配到ZS组或安慰剂组。干预组女性从月经周期的第16天至下一个周期的第2天服用220毫克ZS胶囊（含50毫克元素锌）。使用经前症状筛查工具（PSST）和12项简短健康调查问卷收集数据。
在整个研究期间，ZS组中重度经前综合征的患病率显著下降（研究第一个月为9.5%，第二个月为6%，第三个月为2.6%，P < 0.001），但在对照安慰剂组中，仅在研究的第一个月出现这种下降（第一个月为14.2%，第二个月为13.7%，第三个月为13.5%，P = 0.08）。此外，在整个研究期间，ZS改善了PSST各成分得分。ZS干预组的身体和心理成分的生活质量平均得分显著提高。然而，差异仅在干预3个月后具有统计学意义。
硫酸锌作为一种简单且廉价的治疗方法，与经前综合征症状及健康相关生活质量的改善相关。需要进一步的研究来证实这些发现。
